<DOC>
	<DOCNO>NCT01162993</DOCNO>
	<brief_summary>Rationale : Diabetic neuropathy one common complication Diabetes Mellitus ( DM ) . Pain common symptom diabetic neuropathy , affect 11-34 % patient suffer form DM . The burden disease painful diabetic polyneuropathy ( PDP ) high patient society , due significant pain level , frequent co-morbidity , polypharmacy significant health resource use . Spinal cord stimulation ( SCS ) use 30 year treat neuropathic pain . Several small clinical study show beneficial effect SCS pain PDP . Objective : The primary objective study investigate whether SCS lead clinically relevant ( ≥50 % ) pain relief patient moderate-to-severe PDP low limbs 6 month treatment . Secondary objective investigate 1 ) effect SCS health relate quality life PDP ; 2 ) effect SCS quality sleep PDP ; 3 ) effect SCS mood PDP ; 4 ) effect SCS blood glucose control PDP ; 5 ) effect SCS large small nerve fibre function PDP ; 6 ) identify predictive factor success SCS treatment PDP ; 6 month 7 ) effect SCS small fibre loss regeneration PDP ; 8 ) cost , cost-utility cost-effectiveness 12 month treatment . Study design : study multi centre randomize control trial . Study population : Patients suffer moderate-to-severe PDP low limb due diabetes mellitus type 1 type 2 diagnose clinical symptom ( glove stock distribution ) . Intervention : patient assign group 1 receive spinal cord stimulation ( SCS ) and/or best ( drug ) treatment possible , patient assign group 2 receive best ( drug ) treatment possible . Main study parameters/endpoints : The main study parameter mean pain intensity and/or maximal pain intensity daytime and/or night time measure weighted NRS and/or PGIC pain sleep measure 7-point Likert scale , 6 month treatment . Nature extent burden risk associate participation , benefit group relatedness : SCS related risk include : lead migration ( 14 % ) , lead breakage ( 7 % ) , implant pulse generator migration ( 1 % ) , loss therapeutic effect , lose unpleasant paresthesia ( 12 % ) , infection wind breakdown ( 10 % ) , Pain IPG incision site ( 12 % ) , IPG pocket fluid collection ( 5 % ) . Treatment-as-usual related risk related medication use increase due participation study .</brief_summary>
	<brief_title>Effect Spinal Cord Stimulation ( SCS ) Painful Diabetic Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Moderatetosevere PDP low limbs The pain intend treat present 12 month Previous treatment unsuccessful ( insufficient pain relief and/or unacceptable sideeffects ) drug follow drug category : Amitriptylin tricyclic antidepressant and/or Pregabalin ( Lyrica® ) Gabapentin ( Neurontin® ) and/or Duloxetine ( Cymbalta® ) and/or Tramadol strong opioids Patients treat 3 drug mention drug category follow treatment algorithm painful diabetic polyneuropathy accord Jensen . Starting dosage base individual patient characteristic . Each drug try least 3 week dose raise , possible . By insufficient pain relief and/or unacceptable sideeffects , drug treatment stop . Patients reach steady state medication use allow increase dosage study . Mean pain intensity daytime and/or night time 5 high measure numeric rating scale ( NRS ) . Pain daytime score 3 time per day 4 day accord Jensen . Patient 's age 18 75 year . The patient neuromodulation therapy month intake Neuropathic pain prevalent upper limb ( NRS &gt; 3 ) Neuropathy chronic pain origin diabetes mellitus ( NRS &gt; 3 ) Addiction : drug , alcohol ( &gt; 5E / day ) and/or medication Drugs : cocaine , heroine , marihuana . Alcohol : wine , beer , liquor ( max 5E / day ) Medication : benzodiazepine . Insufficient cooperation patient ( little motivation , understand communication ) Blood clot disorder , use 2 different kind anti coagulation Immune deficiency ( HIVpositive , corticosteroid dose equivalent &gt; prednisolone 10 mg , immunodepressive , etc . ) Peripheral vascular disease without palpable peripheral pulse foot ( inclusion possible pulse absent , ankle brachial index 0.7 1.2 foot ) Active foot ulceration Life expectancy &lt; 1 year Pacemaker Local infection skin disorder site incision Psychiatric problem potentially interfere cooperation study Pregnancy Severe cardiac pulmonary failure ( &gt; NYHA classification II ) Unstable blood glucose control ( change HbA1c &gt; 1,0 % three month prior inclusion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Electric stimulation therapy</keyword>
	<keyword>Diabetic Neuropathies</keyword>
</DOC>